Megan Molteni

Megan Molteni is a science writer at STAT who covers how advances in genomic medicine and neuroscience intersect with power, policy, and inequity in health. Her reporting stands out for connecting cutting-edge research — from synthetic genomes to brain development — with the structures that determine who benefits, who is harmed, and how scientific decisions reverberate through society. Across her work, she treats health stories as stories about systems, tracing the links between molecular findings, funding decisions, and long-term outcomes for patients and communities.

Intersection of science and society

Megan’s stated focus is the intersection of science and society, with particular attention to how biomedical research is funded, who benefits, and how power within science shapes what questions get asked and answered. She has co-written a multi-part examination of how proposed cuts to federal research funding under the Trump administration exposed the brittleness of the American research enterprise, showing how shifts in budgets ripple through labs, training pipelines, and future treatments. In another feature, she reports on how dangerous eugenic ideas spread while federal health agencies fell silent, detailing how dismantled communications teams weakened public education and left room for pseudoscience to gain traction. She also writes about how the Covid-19 pandemic reshaped collaboration and competition in science, focusing on how new alliances, rivalries, and incentive structures are changing the way research is conducted and shared.

That systems lens runs through her health coverage. When she writes about major disease areas, she frequently foregrounds questions of access, oversight, and responsibility rather than limiting the story to clinical trial results or narrow efficacy metrics. In her piece asking when patients should stop taking a newly approved Alzheimer’s drug, for example, she examines not only the neuroscience behind the therapy but also the gaps in guidance, the risks of prolonged treatment, and the practical dilemmas facing clinicians and families. Her work often treats scientific advances as political and ethical events, requiring scrutiny of regulatory decisions, institutional priorities, and the broader communication ecosystem around them.

Genomic medicine, synthetic biology, and the human genome

Megan covers genomic medicine in depth, from foundational resources like the human genome reference to experimental therapies and diagnostics at the edge of clinical practice. In a feature on the first human “pangenome,” she explains how building a more representative reference genome — with DNA from diverse populations — changes what scientists can see about disease risk and genetic variation, and why inclusion matters for future treatments. She has reported on newborn DNA sequencing programs that identify hidden disease risk early in life, documenting how families and clinicians weigh the benefits of advanced screening against questions of consent, uncertainty, and health-system capacity.

Her coverage extends into synthetic biology, where she has written about researchers who swapped the DNA of Escherichia coli for a fully redesigned genetic code and then engineered the bacteria to be virtually impervious to viral infection. In that story, she walks readers through how altering codons and tRNAs can both block bacteriophage attacks and enable cells to build proteins with non-natural amino acids, showing the implications for biomanufacturing and biosecurity. She also maintains a detailed guide to CRISPR advances, tracking how gene-editing tools are moving from the lab into clinical trials, what technical hurdles remain, and how regulatory and ethical debates are unfolding around their use. More recently, she has covered work reconstructing “family trees” of blood cells to predict disease risk years before symptoms, focusing on how tracking somatic mutations in real time might change screening strategies and long-term monitoring.

Neuroscience, brain health, and therapeutics

Neuroscience is another core strand of Megan’s beat, with stories that connect molecular mechanisms to lived experience and policy decisions. In her reporting on Huntington’s disease, she follows scientists who revisit overlooked clues in the gene’s behavior — such as somatic expansion of CAG repeats and the production of smaller, toxic protein fragments — to open new avenues for treatment. Her Alzheimer’s coverage centers on practical, unresolved questions like when to discontinue a high-profile drug, highlighting uncertainties in trial data, risks of side effects, and the absence of clear stopping rules in regulatory guidance.

She also writes about how social conditions shape brain development and health outcomes, including work showing the influence of socioeconomic status on children’s brain development over time. In those pieces, she links neuroimaging and cognitive measures to broader questions about inequality, environment, and the long tail of early-life disadvantage. Across these stories, she treats brain science not as isolated lab findings but as evidence embedded in school systems, housing policies, and health-care access.

Public health, HIV, and infectious disease

Megan’s earlier and ongoing work includes significant public health reporting, often at the point where infectious disease research meets questions of equity and communication. She has covered cases where individuals living with HIV show signs of “natural” viral control or cure, exploring what such rare outcomes mean for research on new therapies and how they challenge existing understandings of the virus. Her pandemic reporting, including on how collaboration and competition in science shifted during Covid-19, looks closely at how crises accelerate certain kinds of research while exposing structural weaknesses in others.

Before joining STAT, she worked as a staff writer covering biotechnology, public health, and genetic privacy, which informs her current focus on the consequences of data-intensive medicine and large-scale health surveillance. That background shows in her attention to privacy, consent, and governance whenever she reports on genomic datasets, newborn screening programs, or long-term tracking of cellular mutations and disease risk. Overall, her body of work offers a consistent thread: using health stories to interrogate how scientific power is exercised, who it serves, and how its benefits and harms are distributed.